Tempus AI (TEM) Stock Analysis & Winston Score

Tempus AI is a healthcare technology company that collects and analyzes medical data — especially from cancer patients — to help doctors make better treatment decisions. Its main products include a genomic testing service that sequences tumor DNA, and a data platform that hospitals and pharmaceutical companies use to run research and clinical trials. It is one of the largest collectors of clinical and molecular data in the United States. Tempus makes money by charging for genomic tests ordered by oncologists, and by licensing its large database of de-identified patient data to drug companies and researchers on a subscription or contract basis. The company operates primarily in the United States and generated roughly $700 million in annual revenue, though it is not yet profitable. Its main competitive advantage is the sheer size of its proprietary dataset, which is hard for rivals to replicate quickly. The key risk is its continued losses, as the company must keep spending heavily on data collection and AI development before reaching profitability.